Milo Biotechnology, a Cleveland, Ohio-based clinical stage company developing therapies to strengthen muscle of patients with neuromuscular diseases, raised a funding round of undisclosed amount.
Backers included JumpStart’s Evergreen Fund and Rev1 Ventures’ Catalyst Fund.
The company intends to use the funds to prepare for multi-center pivotal clinical trials, which could begin in late 2017.
Founded in 2012 by CEO Al Hawkins and Brian Kaspar, Milo Biotechnology has been developing a gene-therapy program which uses a version of the protein follistatin to treat the muscle atrophy commonly associated with muscular dystrophies.
The program is based on clinical expertise that originates out of Columbus’ Nationwide Children’s Hospital.